This is completely last minute, due to your organizer spacing out, but we are hosting another joint meetup with NYC Health Data Scientists (http://www.meetup.com/NYC-Health-Data-Scientists/events/147957302/) happening TONIGHT:
Aditya Mukerjee presents …. BoardRounds
Aditya is the co-founder and CTO of BoardRounds, which provides transitional care management as service to hospitals, ensuring timely post-discharge followup with outpatient physicians. BoardRounds provides analytics that allow payers to offer dynamic incentives to providers to facilitate appropriate followup care based on a patient's estimated risk of further acute care. In addition, BoardRounds allows hospitals timely access to data on relevant metrics such as length-of-stay and readmission rates.
Knut M. Wittkowski presents …From Epilepsies to Autism: New Methods to Find Missing Heritability in Disease
Dr. Wittkowski foresaw the opportunities for a class of non-parametric statistical methods whose application to multivariate data had been abandoned in the 1940s because of high memory demand. His expansion of u-statistics to reflect structures among variables was successfully applied to sports, consumer preferences, and images, as well as complex phenotypes in Fanconi anemia, psoriasis, and shock.
Reflecting structures among SNPs (Single Nucleotide Polymorphisms) increases the power of wide-locus GWAS (Genome Wide Association Studies) to detect functional information about genomic pathways. While conventional analyses of autism GWAS had been essentially inconclusive, a reanalysis of subgroups using a novel computational biostatistics approach provided novel insights into the shared etiology with epilepsies and suggested the first treatment approach to prevent progression to the more severe end of the spectrum.
With sample size requirements reduced to a few hundred subjects only by combining phenotype and genotype structures within the statistical method, patients at risk of adverse events and/or treatment failure can now be identified from the data gathered in phase III studies, so that companion tests can bring "failed" drugs back to market.